Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Overview

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor [neurons](/entities/neurons) in the brain and spinal cord[@brown2017]. The disease leads to gradual muscle weakness, paralysis, and typically results in death within 2-5 years of symptom onset due to respiratory failure[@chio2009]. ALS represents the most common adult-onset motor neuron disease, with an incidence of approximately 1-2 per 100,000 persons annually and a prevalence of 4-8 per 100,000[@marin2017].

The clinical presentation of ALS is heterogeneous, with patients typically presenting with focal weakness that progresses in a regional pattern before becoming generalized[@kiernan2011]. Common initial symptoms include limb weakness (60-70% of cases), bulbar involvement (25-30%), and respiratory insufficiency (5-10%)[@chio2015]. The disease follows an ascending pattern of progression, with contiguous body regions becoming affected over time[@ravits2007].

Epidemiology

Incidence and Prevalence

ALS exhibits a uniform worldwide incidence of approximately 1-2 cases per 100,000 population per year, with notable geographic variations[@alchalabi2016]. The mean age of onset is 55-65 years for sporadic ALS and approximately 10 years earlier for familial cases[@chi2008]. Population-based studies indicate a slight male predominance (1.2-1.5:1 ratio), which is most pronounced in patients under 70 years of age[@manjaly2010].

Amyotrophic Lateral Sclerosis (ALS)

Overview

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor [neurons](/entities/neurons) in the brain and spinal cord[@brown2017]. The disease leads to gradual muscle weakness, paralysis, and typically results in death within 2-5 years of symptom onset due to respiratory failure[@chio2009]. ALS represents the most common adult-onset motor neuron disease, with an incidence of approximately 1-2 per 100,000 persons annually and a prevalence of 4-8 per 100,000[@marin2017].

The clinical presentation of ALS is heterogeneous, with patients typically presenting with focal weakness that progresses in a regional pattern before becoming generalized[@kiernan2011]. Common initial symptoms include limb weakness (60-70% of cases), bulbar involvement (25-30%), and respiratory insufficiency (5-10%)[@chio2015]. The disease follows an ascending pattern of progression, with contiguous body regions becoming affected over time[@ravits2007].

Epidemiology

Incidence and Prevalence

ALS exhibits a uniform worldwide incidence of approximately 1-2 cases per 100,000 population per year, with notable geographic variations[@alchalabi2016]. The mean age of onset is 55-65 years for sporadic ALS and approximately 10 years earlier for familial cases[@chi2008]. Population-based studies indicate a slight male predominance (1.2-1.5:1 ratio), which is most pronounced in patients under 70 years of age[@manjaly2010].

The prevalence of ALS ranges from 4-8 per 100,000, with this figure relatively stable across populations despite the uniformly fatal outcome[@logroscino2017]. This relatively constant prevalence reflects the short survival duration, with median survival from symptom onset being 2-4 years and only 10-20% of patients surviving beyond 5 years[@kimura2023].

Risk Factors

Epidemiological studies have identified several risk factors for ALS, though the etiology remains incompletely understood in the majority of cases. Approximately 5-10% of ALS cases are familial, following autosomal dominant inheritance with incomplete penetrance[@mathis2019]. The remaining 90-95% are classified as sporadic, with no clear family history.

Environmental factors implicated in ALS pathogenesis include smoking, which increases risk by approximately 1.5-2-fold[@wang2017]. Physical activity has shown inconsistent associations, with some studies suggesting increased risk in elite athletes and others showing protective effects of moderate exercise[@lacorte2020]. Other potential risk factors include exposure to heavy metals, pesticides, and head trauma, though evidence remains inconsistent[@bozzoni2016].

Genetics

Familial ALS Genes

Approximately 5-10% of ALS cases are hereditary, with over 25 genes implicated in familial ALS[@brennan2023]. The major causative genes include:

[C9orf72](/genes/c9orf72) — The most common genetic cause of ALS worldwide, accounting for approximately 40% of familial ALS and 5-10% of sporadic ALS[@renton2011]. Hexanucleotide repeat expansions in the first intron of C9orf72 represent the most frequent mutation, with >30 repeats considered pathogenic. The normal allele contains <30 repeats, while affected individuals may have hundreds to thousands of repeats[@dejesushernandez2011]. This mutation also causes [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia), explaining the clinical overlap between these disorders.

[SOD1](/genes/sod1) — Mutations in the copper/zinc superoxide dismutase gene account for approximately 12-20% of familial ALS[@rosen1993]. Over 150 pathogenic SOD1 variants have been identified, with the A4V mutation being the most common in North America and associated with rapid disease progression[@cudkowicz1999]. SOD1 mutations cause disease through toxic gain-of-function mechanisms rather than loss of enzymatic activity.

[FUS](/genes/fus) — Mutations in the fused in sarcoma gene account for approximately 5% of familial ALS[@kwiatkowski2009]. Most mutations are clustered in the nuclear localization sequence and lead to cytoplasmic mislocalization of FUS protein. FUS mutations are associated with earlier disease onset (median 39 years) and more rapid progression compared to other genetic forms[@conte2012].

[TARDBP](/genes/tardbp) — Mutations in the TAR DNA-binding protein gene (TARDBP) account for approximately 3-5% of familial ALS[@sreedharan2008]. Like FUS, TARDBP mutations cause cytoplasmic accumulation of [TDP-43 protein](/mechanisms/tdp-43-proteinopathy), which is the major component of inclusion bodies in most ALS cases[@neumann2006].

Sporadic ALS Genetics

Genome-wide association studies (GWAS) have identified multiple risk loci for sporadic ALS, though effect sizes are modest[@nicolas2018]. The strongest associations include:

• UNC13A — Variants in this gene modify disease progression and survival in ALS[@diekstra2012]
• ATXN2 — Intermediate CAG repeats increase ALS risk approximately 2-fold[@soraru2013]
• DAXX — Recent GWAS has identified this gene as a novel ALS risk factor[@van2023]

Pathophysiology

Motor Neuron Degeneration

ALS is characterized by the selective degeneration of both upper motor neurons (corticospinal tract neurons) and lower motor neurons (anterior horn cells and bulbar motor nuclei)[@hardiman2017]. The pattern of involvement is focal initially, spreading contiguously to adjacent regions over time[@ravits2009]. This propagation may occur through prion-like templating of protein aggregates or through neural network connections[@polymenidou2012].

The pathological hallmarks of ALS include:

• Loss of motor neurons — Progressive death ofcortical and spinal motor neurons with accompanying gliosis[@charcot1969]
• Bunina bodies — Small, intracytoplasmic inclusions found in approximately 70% of cases[@bunina1962]
• TDP-43 inclusions — Ubiquitinated inclusions containing phosphorylated TDP-43 in approximately 95% of ALS cases (both sporadic and most familial forms except SOD1)[@arai2006]
• Dystrophic neurites — Abnormal neuronal processes surrounding inclusion bodies[@dickson2007]

Molecular Mechanisms

Multiple interconnected pathogenic mechanisms contribute to motor neuron degeneration in ALS:

RNA Metabolism Dysregulation — Mutations in RNA-binding proteins (TDP-43, FUS) disrupt normal RNA processing, including splicing, transport, and translation[@ling2013]. These defects lead to abnormal protein aggregation and loss of function for critical neuronal proteins[@lagiertourenne2009].

Oxidative Stress — Motor neurons are particularly vulnerable to oxidative damage due to high metabolic demands and relatively low antioxidant capacity[@barber2010]. SOD1 mutations directly increase oxidative stress, and evidence of oxidative damage to proteins, lipids, and DNA is found in both familial and sporadic ALS[@andrus1998].

Excitotoxicity — Excessive glutamate signaling through AMPA and NMDA receptors can lead to calcium influx and excitotoxic cell death[@van2009]. The finding that riluzole (an anti-glutamatergic drug) provides modest survival benefit supports this mechanism[@bensimon1994].

Mitochondrial Dysfunction — Abnormal mitochondria with reduced function are consistently observed in ALS motor neurons[@mrotz2022]. This defect leads to energy failure, increased [reactive oxygen species](/entities/reactive-oxygen-species) production, and activation of apoptotic pathways[@pizzuto2019].

Impaired Proteostasis — Both TDP-43 and SOD1 aggregates indicate failure of protein quality control systems[@chen2022]. [Autophagy](/entities/autophagy) and [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system) dysfunction allows toxic protein accumulation[@wong2014].

Neuroinflammation — Activated [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes) surround motor neurons in ALS, producing pro-inflammatory cytokines that may contribute to disease progression[@huang2022].

Clinical Presentation

Initial Symptoms

ALS typically presents with insidious onset of focal weakness, with the pattern reflecting the region of initial motor neuron involvement[@chio2014]. The most common presentations include:

Limb-onset ALS (70%) — Weakness beginning in one limb, typically presenting as foot drop, hand weakness, or proximal arm weakness. Fasciculations and muscle atrophy often accompany the weakness[@eisen2001].

Bulbar-onset ALS (25-30%) — Difficulty with speech (dysarthria) and swallowing (dysphagia) as initial symptoms. Tongue fasciculations and weakness are characteristically present[@krner2011].

Respiratory-onset ALS (5-10%) — Presents with dyspnea, orthopnea, or nocturnal hypoventilation. This presentation carries the poorest prognosis[@chio2010].

Disease Progression

Following onset, ALS progresses in a predictable pattern with involvement of adjacent body regions. Progression typically follows a contiguity model, with adjacent spinal segments affected in sequence[@ravits2021]. However, the pattern and rate of progression vary considerably between individuals.

The progression leads to:

• Generalized muscle weakness and paralysis
• Severe muscle atrophy and fasciculations
• Dysarthria and dysphagia leading to nutritional compromise
• Respiratory muscle weakness requiring ventilatory support
• Cognitive and behavioral changes in approximately 15% of cases (ALS-FTD spectrum)[@phukan2007]

Diagnostic Criteria

The El Escorial revised criteria and Awaji criteria provide standardized diagnostic classification for ALS[@world2000][@costa2012]:

Definite ALS — Presence of upper and lower motor neuron signs in three body regions (bulbar, cervical, thoracic, lumbosacral)

Probable ALS — Upper and lower motor neuron signs in at least two regions, with some signs in one region extending to another

Possible ALS — Upper and lower motor neuron signs in one region, or upper motor neuron signs in two regions, or lower motor neuron signs in two regions

Suspected ALS — Lower motor neuron predominance in two or more regions

Diagnosis

Clinical Evaluation

Diagnosis of ALS is primarily clinical, based on history, neurological examination, and electrophysiological studies[@efns2012]. The diagnostic process involves:

History — Progressive muscle weakness, typically starting in one body region and spreading contiguously. Presence of fasciculations, cramps, and difficulty with fine motor tasks[@benatar2019].

Neurological Examination — Evidence of both upper motor neuron signs (hyperreflexia, spasticity, pathological reflexes) and lower motor neuron signs (weakness, atrophy, fasciculations)[@swinnen2014].

Electrophysiology — Needle electromyography shows widespread denervation and reinnervation consistent with motor neuron disease. Nerve conduction studies are typically normal, helping to exclude peripheral neuropathies[@de2008].

Diagnostic Tests

While no definitive test for ALS exists, several investigations support the diagnosis and rule out mimics:

MRI Brain and Spine — Rule out structural lesions, compression, or alternative pathologies. May show corticospinal tract hyperintensity or signal changes in ALS[@chang2005].

Genetic Testing — Increasingly important for diagnosis, prognostication, and family counseling. Testing for C9orf72, SOD1, FUS, and TARDBP is available[@chio2012].

Laboratory Tests — Routine blood work to exclude metabolic, inflammatory, and infectious mimics. Anti-GM1 antibodies may be present in motor neuropathy variants[@liguori2022].

Treatment

Disease-Modifying Therapies

Riluzole — The first FDA-approved disease-modifying therapy for ALS, approved in 1995. Riluzole inhibits glutamate release and reduces glutamatergic neurotransmission[@dambach2022]. Clinical trials demonstrate modest survival benefit (2-3 months) with minimal functional improvement[@miller2012].

Edaravone — Approved by FDA in 2017 based on randomized controlled trial showing slower functional decline in patients receiving intravenous edaravone[@writing2017]. The mechanism involves reduction of oxidative stress, though the exact therapeutic effect remains incompletely understood[@yoshino2021].

AMX0035 (sodium phenylbutyrate/taurursodiol) — Approved in 2022 based on the CENTAUR trial showing significant survival benefit (median 4.8 months) and slower functional decline[@paganoni2023].

Relyvrio (AMX0035) — FDA approved combination therapy that targets mitochondrial dysfunction and energy failure in ALS[@fda2022].

Symptomatic Management

Comprehensive multidisciplinary care is essential for optimal outcomes in ALS:

Respiratory Care — Non-invasive ventilation (BiPAP) improves survival and quality of life in patients with respiratory dysfunction[@bourke2006]. Bulbar dysfunction may require volume ventilation. Timely discussion of tracheostomy and long-term ventilation is important[@hardiman2011].

Nutritional Support — Malnutrition worsens outcomes in ALS. Percutaneous endoscopic gastrostomy (PEG) placement provides reliable nutrition when oral intake becomes unsafe or insufficient[@naito2023].

Spasticity Management — Baclofen, tizanidine, and benzodiazepines provide symptomatic relief for spasticity. Botulinum toxin injections may help focal spasticity[@dal1998].

Communication Aids — Augmentative and alternative communication devices become essential as speech fails. Eye-tracking and brain-computer interfaces provide communication options[@beukelman2011].

Experimental Approaches

Multiple therapeutic strategies are under investigation:

Gene Therapy — Antisense oligonucleotides targeting SOD1 (tofersen) have shown promise in clinical trials, with recent positive results supporting accelerated approval[@miller2023]. Gene therapy approaches for C9orf72 and other genetic forms are in development[@liu2023].

Cell-Based Therapies — Clinical trials of stem cell transplantation have explored neuroprotective and immunomodulatory approaches, though definitive benefits remain elusive[@goutman2023].

Small Molecule Drugs — Numerous compounds targeting various pathogenic mechanisms are in clinical trials, including mitochondrial protectors, anti-excitotoxic agents, and anti-inflammatory compounds[@jaiswal2019].

Research Directions

Biomarker Development

Reliable biomarkers for diagnosis, prognosis, and therapeutic monitoring remain an urgent need in ALS. Promising biomarker candidates include:

[Neurofilament Light](/biomarkers/neurofilament-light-chain-nfl) Chain (NfL) — Elevated in cerebrospinal fluid and blood, correlates with disease progression and survival[@benatar2021]. NfL shows promise for monitoring treatment response in clinical trials[@lu2019].

Genetic Biomarkers — C9orf72 repeat size, SOD1 mutation type, and other genetic factors influence prognosis and may predict treatment response[@chio2015a].

Clinical Trial Design

Recent advances in trial methodology include:

Platform Trials — Master protocols allowing multiple simultaneous treatments within a single trial structure, improving efficiency[@ivanova2023].

Enrichment Strategies — Selecting patients based on genetic subtypes or biomarkers may improve signal detection[@van2019].

Outcome Measures — Development of more sensitive clinical endpoints and patient-reported outcomes[@benatar2023].

Conclusion

Amyotrophic lateral sclerosis represents a devastating neurodegenerative disease with profound impacts on patients, families, and healthcare systems. While our understanding of ALS pathogenesis has advanced considerably—from the identification of major genetic causes to elucidation of molecular mechanisms—no curative treatment exists. The development of disease-modifying therapies including riluzole, edaravone, and AMX0035 provides hope, while emerging gene therapies and immunomodulatory approaches offer promise for the future. Comprehensive multidisciplinary care remains essential for optimizing quality of life and survival in ALS patients.

Pathway & Interaction Diagram

Interactive diagram showing Als's key relationships in the SciDEX knowledge graph (15 connections shown).

See Also

• [Primary Lateral Sclerosis](/diseases/primary-lateral-sclerosis)
• [Progressive Muscular Atrophy](/diseases/progressive-muscular-atrophy)
• [Flail Arm Syndrome](/diseases/flail-arm-syndrome)
• [Flail Leg Syndrome](/diseases/flail-leg-syndrome)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [Mitochondrial Dysfunction in Neurodegenerative Diseases Comparison](/diseases/mitochondrial-dysfunction-neurodegeneration-comparison)
• [TDP-43 protein](/mechanisms/tdp-43-proteinopathy)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References